Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Personalized Active Immunotherapy (Vaccine Therapy) and Sargramostim Given After Standard of Care Treatment With Rituximab and Chemotherapy for Initial Treatment With Lymphoma

This study has been terminated.
Sponsor:
Information provided by:
Genitope Corporation
ClinicalTrials.gov Identifier:
NCT00510471
First received: July 31, 2007
Last updated: March 14, 2008
Last verified: March 2008
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: No date given